Sexually Transmitted Diseases

Some rural counties with historically low rates of HIV infection are now experiencing increased risks for HIV transmission of the virus and do not have the infrastructure or resources to respond appropriately.

The first step (prime) is to immunize with conventional vaccines through a needle in the arm. The second step (pull), is to apply an antibiotic cream that helps attract, T cells, to the site of virus growth.

Initiating and adhering to ART is a difficult task for a significant number of people living with HIV. A new study shows that making a concerted effort to find and encourage this population to get the care they need is not an impossible dream.

The adjusted hazard ratios for 1-dose and 2-dose recipients were comparable to the 3-dose recipients (1 dose 1.01 [95%CI 0.81–1.26], 2 doses 1.00 [0.85–1.17]) after adjusting for age at vaccination among the vaccinated group.

The percentage of participants who achieved HIV-1 RNA< 50 copies/mL in the 0.25 mg, 0.75 mg, 2.25 mg MK-8591 dose groups was 89.7%, 90.0%, and 77.4%, respectively, at week 48.

A sharp increase in syphilis cases in Europe is hitting hardest among MSM and has been linked to the use of PrEP drugs and an increase in risky sexual behavior.

Providers’ communication styles and level of knowledge about HIV have a significant impact on whether patients begin and remain in treatment.

At week 48, 83.8% of participants in the TAF/FTC/DTG arm had HIV RNA < 50 copies/mL, 84.9% for TDF/FTC/DTG and 78.6% for TDF/FTC/EFV.

The final results of HOPE, a phase 3 open-label extension trial, show high uptake and lower-than-anticipated HIV-1 incidence.

New results indicate that the study met its primary end point for non-inferiority based on the proportion of participants with plasma HIV-1 RNA > 50 copies per mL at week 48.

The investigators observed durable humoral immune responses over 2 years with a response rate of 100% in participants receiving the Ad26.Mos.HIV, gp140HD vaccine regimen.

With 1329.6 person-years of PrEP use accumulated, early continuation was achieved by 79.8% of participants.

Providers who received the intervention materials had higher satisfaction and confidence in prescribing chronic opioid therapy than their colleagues who did not.

Two phase 3 studies presented at IAS 2019 evaluated a switch to B/F/TAF among individuals virologically suppressed on other HIV treatment regimens.

The team assessed program engagement, medication refills, and self-reported 3-day adherence over 72 weeks, among the individuals who initiated PrEP.

The guidelines include a new section featuring recommendations for treating transgender people living with HIV.

Long-acting reservoir-style PrEP implants could help solve adherence issues.

PrEP awareness among these MSM rose from 60% to 90% from 2014 to 2017, and PrEP use increased from 6% to 35%.

New research assesses potential alternatives to a daily dose of emtricitabine/tenofovir. It finds mixed results.

The program combines PrEP administration along with evidence-based behavioral intervention to reduce HIV risk behavior for HIV-negative, opioid-dependent people who use drugs and are receiving treatment.

Interest in on-demand HIV pre-exposure prophylaxis may be increasing, according to a survey in Australia.

Investigators sought to identify potentially intervenable factors that affect mortality among PLWH in the city of San Francisco.

Getting PrEP into the hands of those who stand to gain the most from it, including women in sub-Saharan Africa remains a challenge.

The investigators used a combined approach of LASER ART and CRISPR-Cas9 to successfully eliminate replication-competent HIV-1 DNA from the genome of living mice.

The FDA approved the first darunavir-based single-tablet regimen for the treatment of HIV in July 2018. How is it working out for patients and providers alike?